Navigation Links
Ambry Genetics Launches New Neurodevelopmental Genetic Testing Panel
Date:1/20/2016

ALISO VIEJO, Calif., Jan. 20, 2016 /PRNewswire/ -- Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, today announced that it is launching a new suite of five genetic tests for neurodevelopmental conditions. These can be ordered starting on January 20, and follow the launch of Ambry's epilepsy testing in November 2015. All build on the company's growing portfolio of neurological diagnostic solutions.

Neurodevelopmental disorders (NDDs) affect more than 4.6 million Americans,1 and include a range of conditions associated primarily with the functioning of the brain and neurological system. These include developmental delays, intellectual disability (ID), and autism spectrum disorders (ASDs).

"Neurodevelopmental disorders are generally difficult to subtype," said Michael Raff, MD, a medical geneticist at the Mary Bridge Children's Health Center in Tacoma, WA.  "Ambry has offered their well-regarded tiered testing for making a specific diagnosis, enabling physicians to choose the best diagnostic approach for each affected individual."

Disorders of the central nervous system can significantly affect learning, behavior, and emotions, and often develop as a child grows.  In many cases, genetic testing may help identify an underlying cause, which is why leading medical associations recognize the importance of genetic testing for all children with ID and ASDs.2,3,4,5  Ambry's diagnostic options incorporate this scientific evidence, offering a unique tiered approach with the option of starting with targeted tests and moving to broader options.

Ambry's new tests include:

  • IDNext: a broad panel of 140 genes known to be associated with both syndromic and non-syndromic ID
  • AutismFirst: a targeted panel of 16 genes recognized by the American College of Medical Genetics and Genomics (ACMG) as associated with syndromic ASDs
  • AutismNext: a broader panel of 48 genes that can cause both syndromic and non-syndromic ASDs
  • Neurodevelopment-Expanded: a broad panel of 196 genes designed for patients who have a combination of ID, ASDs, and epilepsy
  • Rett/AngelmanNext: a panel of 22 genes known to cause symptoms of multiple overlapping neurodevelopmental disorders, including Rett syndrome and Angelman syndrome

Ambry's new options enhance the company's existing neurodevelopmental menu, which includes:

  • Chromosomal microarray: assesses for genetic imbalances that can cause ID, ASD, and epilepsy
  • Fragile X-associated disorders: identifies mutations in a single gene (FMR1) associated with ASDs, behavioral changes, and cognitive impairment
  • PTEN-related disorders: detects mutations causing ASDs in conjunction with macrocephaly
  • ExomeNext and ExomeNext-Rapid: clinical diagnostic exome sequencing that analyzes up to 20,000 genes concurrently; can be beneficial for patients with NDDs who have had prior uninformative results with symptom-specific genetic testing

"At Ambry, we are building a portfolio of neurological genetic testing options, starting with epilepsy and now NDDs, which offer healthcare providers flexibility. We recognize that testing needs differ for patients," said Amanda Bergner, MS, CGC, Senior Neurology Product Manager at Ambry. "Neurodevelopmental disorders can be challenging to diagnose because symptoms often overlap and are not specific to any one NDD. We are proud to offer this new product line to provide clinicians with more tools to arrive at an accurate diagnosis, and look forward to continually expanding our neurology testing menu."

To receive more information about Ambry's neurodevelopmental genetic testing offerings, please visit http://www.ambrygen.org/client-information-web-form to complete an information request form. 

ABOUT AMBRY GENETICS®
Ambry Genetics is a privately-held healthcare information company with the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases.  Since 1999, Ambry has tested approximately half a million patient samples benefiting 90% of all U.S. patients covered by public and private insurers.  Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified.  The company leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com

Contacts:
Ambry Genetics
Humberto Huerta
Director of Marketing
hhuerta@ambrygen.com
949-900-5516

Ogilvy Public Relations
Katy Culver
katy.culver@ogilvy.com
212-880-5361

References:

  1. Larson SL, et al. Prevalence of mental retardation and/or developmental disabilities: Analysis of the 1994/1995 NHIS-D. MR/DD Data Brief. Minneapolis, MN: Institute on Community Integration, University of Minnesota. 2000
  2. Moeschler JB, et al. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics. 2014 Sep;134(3):903-918.
  3. Miller DT, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010 May 14;86(5):749-764.
  4. Schaefer GB, et al. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013 May;15(5):399-407.
  5. Michelson DJ, et al. Evidence report: Genetics and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2011 Oct 25;77(17):1629-1635.

Logo - http://photos.prnewswire.com/prnh/20160114/322413LOGO


'/>"/>
SOURCE Ambry Genetics
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. KHB Shanghai Kehua Bio-Engineering Acquires the Italian Technogenetics
2. KHB Shanghai Kehua Bio-Engineering acquiert la société italienne Technogenetics
3. Marc Coucke führt Serie-C-Finanzierungsrunde für Sophia Genetics an
4. Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the Board of Directors
5. First US Commercial Appointment: Atlas Genetics Appoints Keith Stauffer as VP Sales & Marketing
6. Sigma-Aldrich Collaborates with GENEWIZ and Oxford Genetics to Speed Ordering Process for DNA Services
7. Epigenetics Market Size to Reach $16.31 Billion By 2022: Grand View Research, Inc.
8. VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics
9. Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis
10. Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease
11. SpectraGenetics Joins IntelliCyt’s Technology Alliance Partner Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2019)... ... October 29, 2019 , ... Modality Solutions, a ... cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November 11-12, ... The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology providers, ...
(Date:10/26/2019)... (PRWEB) , ... October 24, 2019 , ... ... investment in Bichsel Medical Marketing Group (BMMG), a boutique healthcare-specific marketing ... the offerings of its in-house Healthcare Strategy Division. , Healthcare clients in pharma, ...
(Date:10/22/2019)... ... ... Catalent, a global leader in clinical supply services, today announced that Ann McMahon, ... panel session titled “Cell and Gene Therapy Logistics” at the upcoming Health and Personal ... 28-30, 2019. , The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes ...
(Date:10/22/2019)... ... , ... DermBiont, a clinical stage microbiome biotechnology company developing ... safety endpoints, with no application site reactions and no adverse events, in a ... tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical response with improvement ...
Breaking Biology Technology:
(Date:11/27/2019)... ... November 26, 2019 , ... Smile Glen Ellyn ... practice for Invisalign® treatment. Invisalign orthodontics uses a series of clear, ... bite, also known as malocclusion, present both functional and cosmetic concerns. Functionally, ...
(Date:11/22/2019)... BUFFALO, N.Y. (PRWEB) , ... November 21, 2019 ... ... immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step ... and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell ...
(Date:11/19/2019)... Calif. (PRWEB) , ... November 19, 2019 , ... ... epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), ... a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s ...
Breaking Biology News(10 mins):